{
    "clinical_study": {
        "@rank": "6357", 
        "acronym": "-", 
        "arm_group": [
            {
                "arm_group_label": "Metoprolol Per Oral", 
                "arm_group_type": "Experimental", 
                "description": "50 mg Metoprolol"
            }, 
            {
                "arm_group_label": "Verapamil", 
                "arm_group_type": "Experimental", 
                "description": "40 mg Verapamil Per Oral"
            }, 
            {
                "arm_group_label": "Propranolol", 
                "arm_group_type": "Experimental", 
                "description": "40 mg Propranolol Per Oral"
            }, 
            {
                "arm_group_label": "Diltiazem", 
                "arm_group_type": "Experimental", 
                "description": "60 mg Diltiazem Per Oral"
            }
        ], 
        "brief_summary": {
            "textblock": "Rate control in atrial fibrillation is a usual battle in emergency departments. Oral\n      medications have a natural superiority to intravenous ones because they are easy-to-use and\n      decrease the workload in busy emergency departments.\n\n      This study wants to find an effective oral medication for rate control in rapid ventricular\n      response atrial fibrillation. Propranolol and Metoprolol, Diltiazem and Verapamil are\n      compared in patients with a stable hemodynamic status."
        }, 
        "brief_title": "Rate Control in Atrial Fibrillation", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Rapid Ventricular Response Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age more than 18 years old\n\n          -  Stability in hemodynamic\n\n        Exclusion Criteria:\n\n          -  Systolic blood pressure less than 90 mm Hg\n\n          -  Altered mental status attributable to rapid ventricular response atrial fibrillation\n\n          -  Acute pulmonary edema attributable to rapid ventricular response atrial fibrillation\n\n          -  Chest pain attributable to rapid ventricular response atrial fibrillation\n\n          -  Allergy to Propranolol or Metoprolol or Verapamil or Diltiazem\n\n          -  History of asthma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655303", 
            "org_study_id": "16057"
        }, 
        "intervention": [
            {
                "arm_group_label": "Propranolol", 
                "intervention_name": "Propranolol", 
                "intervention_type": "Drug", 
                "other_name": "Inderal"
            }, 
            {
                "arm_group_label": "Metoprolol Per Oral", 
                "intervention_name": "Metoprolol", 
                "intervention_type": "Drug", 
                "other_name": "Metoral"
            }, 
            {
                "arm_group_label": "Verapamil", 
                "intervention_name": "Verapamil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Diltiazem", 
                "intervention_name": "Diltiazem", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metoprolol", 
                "Verapamil", 
                "Propranolol", 
                "Diltiazem", 
                "Metoprolol succinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "14436151"
                }, 
                "name": "Rasoul-e-Akram Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Oral Propranolol, Diltiazem, Metoprolol and Verapamil in Atrial Fibrillation Rate Control in Patients With Stable Hemodynamic Status", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Ventricular rate less than 100 per minute after 1 hour of per oral medication administration", 
            "measure": "Rate less than 100 per minute", 
            "safety_issue": "No", 
            "time_frame": "In 1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655303"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Drugs adverse effects seen in patients in 2 hours after per oral medication administration", 
                "measure": "Drugs adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "2 hours"
            }, 
            {
                "description": "Hemodynamic instability (systolic blood pressure less than 90 mmHg, loss of consciousness, pulmonary edema, chest pain)", 
                "measure": "Unstability in hemodynamic", 
                "safety_issue": "Yes", 
                "time_frame": "2 hours"
            }
        ], 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}